Chimeric Antigen Receptor T Cells as Living Therapeutics Targeting Senescence and Age-Related Diseases
Research · 01.01.2026 · 9
DOI: 10.34133/research.1326 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Research, online erschienen am 12.06.2026. Verfasst von Qingyi Shao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Ad…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Key Research and Development Program of Zhejiang Province, Construction Fund of Key Medical Disciplines of Hangzhou, Laboratory Diagnostics, Zhejiang Provincial Outstanding Youth Science Foundation.
Abstract (Originalsprache)
The aging of the global population exacerbates the burden of age-related diseases; however, therapies that can intervene in fundamental aging processes are lacking. Senescent cells drive chronic inflammation and multitissue dysfunction through the secretion of proinflammatory and profibrotic senescence-associated secretory phenotype cells, making them emerging therapeutic targets. Although first-generation senolytic drugs have entered clinical trials, they face limitations such as insufficient targeting specificity and transient efficacy. The success of chimeric antigen receptor T cell (CAR T cell) therapy in cancer immunotherapy has validated its precision clearance capabilities as a “living drug”. This review systematically elaborates on the paradigm shift of extending CAR T cell therapy to aging medicine, from the discovery and validation of surface targets on senescent cells to a CAR engineering design tailored to the senescent microenvironment and from evidence of reversing fibrosis and improving metabolic function in preclinical models to the challenges of specificity, safety, and manufacturing faced in clinical translation. Finally, future directions for integrating technologies such as mRNA delivery and artificial intelligence are envisioned in this article, which proposes that CAR T cell therapy may drive the evolution of medicine from “treating single diseases” to “intervening in shared aging processes”, offering transformative strategies to achieve healthy aging.
Autor:innen und Institutionen
- Department of Laboratory Medicine, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou 310052, China.
- Department of Laboratory Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, China.
ORCID-Profile: Qing Ye
Förderung
- Key Research and Development Program of Zhejiang Province
- Construction Fund of Key Medical Disciplines of Hangzhou, Laboratory Diagnostics
- Zhejiang Provincial Outstanding Youth Science Foundation
Zitieren
APA
Shao, Q., Chen, D., Shao, W., & Ye, Q. (2026). Chimeric Antigen Receptor T Cells as Living Therapeutics Targeting Senescence and Age-Related Diseases. Research, 9. https://doi.org/10.34133/research.1326
Vancouver
Shao Q, Chen D, Shao W, Ye Q. Chimeric Antigen Receptor T Cells as Living Therapeutics Targeting Senescence and Age-Related Diseases. Research. 2026;9. doi:10.34133/research.1326
BibTeX
@article{Shao2026,
author = {Shao, Qingyi and Chen, Danlei and Shao, Wenxia and Ye, Qing},
title = {Chimeric Antigen Receptor T Cells as Living Therapeutics Targeting Senescence and Age-Related Diseases},
journal = {Research},
year = {2026},
volume = {9},
doi = {10.34133/research.1326}
}
EUVIMED